We are excited to announce OCCIDENT’s participation in the € 17.9 million Series B funding round of Lymphatica Medtech. The financing round comprises a strong syndicate of experienced MedTech investors and was co-led by Panakes Partners, TechWald Holding and CDP Venture Capital with participation from OCCIDENT, Zürcher Kantonalbank, Club Degli Investitori and existing investors.
Lausanne-based Lymphatica Medtech is a clinical-stage medical device start-up focused on developing novel treatment options for patients suffering from lymphedema. Lymphedema is a common clinical condition with no cure and limited treatment options, often occurring as a side effect after breast cancer treatment.
The company will use the additional funding to further invest in research and development and to finalize and validate the clinical development of its LymphoDrain device. LymphoDrain is the first active implantable device developed for lymphedema therapy and effectively replaces lymphatic drainage without impacting the patients’ lifestyle.
More information in the press release under the following Link
More about Lymphatica
